An Adaptive, Randomized, Placebo-Controlled, Double-Blind, Multi-Center Study of Oral FT-4202, a Pyruvate Kinase Activator in Patients with Sickle Cell Disease (PRAISE)
- Resource Type
- Abstract
- Source
- In
Blood 5 November 2020 136 Supplement 1:19-20 - Subject
- Language
- ISSN
- 0006-4971